(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone | 1198153-15-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone
• 英文别名: UR-1102；(3,5-dibromo-4-hydroxy-phenyl)-(2,3-dihydro-pyrido[4,3-b][1,4]oxazin-4-yl)-methanone；Epaminurad；(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone
• CAS: 1198153-15-9
• 化学式: C₁₄H₁₀Br₂N₂O₃
• 分子量: 414.053
• InChiKey: ZMVGQIIOXCGAFV-UHFFFAOYSA-N

物化性质

• 沸点：
  530.0±50.0 °C(Predicted)
• 密度：
  1.887±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone 在 硫酸 作用下， 以 四氢呋喃 为溶剂， 以69%的产率得到(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone sulfate
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVES

  摘要：

  本发明涉及杂环衍生物，更具体地，涉及用于制备治疗与尿酸相关疾病的药物的新颖杂环衍生物。

  公开号：

  US20110028467A1
• 作为产物：
  描述：

  (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone hydrobromide 在 碳酸氢钠 作用下， 以 水 为溶剂， 以53%的产率得到(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVES

  摘要：

  本发明涉及杂环衍生物，更具体地，涉及用于制备治疗与尿酸相关疾病的药物的新颖杂环衍生物。

  公开号：

  US20110028467A1

文献信息

• URAT1 INHIBITOR
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US20170290795A1

  公开（公告）日：2017-10-12

  Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R 1a , R 2a , R 6a , and R 7a represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, R 3a and R 8a form a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which R 3a and R 8a are bonded, R 4a and R 5a form a benzene ring together with two carbon atoms to which R 4a and R 5a are bonded or represent any of the groups represented by R 1a described above, W a represents CR 10a or N, and where, R 10a represents any of the groups represented by R 1a , X a represents an oxygen atom or a sulfur atom, Y a represents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Z a represents CO 2 H.)

  提供的是以下公式（III）所代表的化合物，该化合物的互变异构体或立体异构体，或者是作为痛风或高尿酸血症治疗剂的药用可接受盐或溶剂。（在公式（III）中，R1a、R2a、R6a和R7a代表氢原子、具有1至8个碳原子的烷基、具有1至8个碳原子的烷氧基或氰基，R3a和R8a形成苯环或含有1至3个杂原子（从氮原子、氧原子和硫原子中选择）的5元杂环，作为环构成元素，与R3a和R8a结合的两个碳原子一起，R4a和R5a与R4a和R5a结合的两个碳原子一起形成苯环，或代表上述R1a描述的任何基团，W代表CR10a或N，其中R10a代表上述R1a描述的任何基团，X代表氧原子或硫原子，Y代表具有1至8个碳原子的烷基链，其中烷基链可能被具有1至8个碳原子的烷基取代，且烷基链可能是直链或支链烷基链，支链烷基链可能由连接到相同或不同的碳原子的侧链形成3至7个成员环，与侧链结合的碳原子以及可能在其中间具有双键，并且Z代表CO2H。）
• Heterocyclic derivatives
  申请人：Ahn Sung Oh

  公开号：US08394792B2

  公开（公告）日：2013-03-12

  Disclosed are heterocyclic derivatives, and more particularly heterocyclic derivatives having the following Formula I which are useful for the preparation of medicaments for treating diseases related to uric acid: wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, L and Y are the same as defined in the detailed description.

  本发明涉及杂环衍生物，特别是具有以下式I的杂环衍生物，其对于制备治疗与尿酸相关疾病的药物是有用的： 式中R1、R2、R3、R4、R5、R6、R7、R8、X1、X2、X3、L和Y的定义与详细描述中定义的相同。
• METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND
  申请人：JW Pharmaceutical Corporation

  公开号：EP3632917A1

  公开（公告）日：2020-04-08

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• HYDROCHLORIDE SALT 1.5 HYDRATE OF AN HETEROCYCLIC DERIVATIVE COMPOUND
  申请人：JW Pharmaceutical Corporation

  公开号：EP3909956A1

  公开（公告）日：2021-11-17

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• A PHARMACEUTICAL COMPOSITION COMPRISING A HETEROCYCLIC DERIVATIVE FOR USE IN THE TREATMENT OF HYPERURICEMIA
  申请人：JW Pharmaceutical Corporation

  公开号：EP3909955A1

  公开（公告）日：2021-11-17

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。